Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by Over 40 Percent

Industry Pulse News Desk · 2026-10-24

Phase 3 clinical trial results indicate individualized messenger RNA therapy significantly reduces cancer relapse in high-risk patients.

A personalized messenger RNA vaccine combined with standard immunotherapy reduced the risk of melanoma recurrence or death by over 40 percent in high-risk patients, according to newly released Phase 3 clinical trial data.

The investigational treatment is designed individually for each patient based on the unique genetic profile of their tumor. By sequencing the patient's cancer DNA, researchers construct a customized mRNA vaccine that instructs the immune system to identify and attack specific neoantigens present in residual tumor cells.

In the late-stage trial, participants who underwent surgical removal of stage III or stage IV melanoma were assigned to receive either the combined personalized mRNA vaccine and standard immunotherapy or standard immunotherapy alone. Patients receiving the combination therapy showed a statistically significant improvement in recurrence-free survival compared to those on monotherapy.

The findings mark a substantial advancement in therapeutic oncology, demonstrating the efficacy of mRNA technology in training patient immune systems to prevent post-surgical cancer relapses. The platform had previously gained widespread adoption for infectious disease vaccines.

Researchers involved in the study indicated that broader applications for other solid tumor types are currently under evaluation. Detailed clinical results are expected to be submitted to global regulatory agencies for prospective approval pathways.